Drug intelligence / Profile preview

cephalothin + tobramycin

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

Cephalothin + tobramycin is an antibiotic combination therapy that pairs a first-generation cephalosporin (cephalothin) with an aminoglycoside (tobramycin). Cephalothin inhibits bacterial cell wall synthesis while tobramycin inhibits bacterial protein synthesis. This combination provides broad-spectrum coverage against both Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. It is used for serious infections such as sepsis, meningitis, respiratory tract infections, intra-abdominal infections, skin infections, bone infections, and complicated urinary tract infections.

Targets

Bacterial RibosomePBP (Penicillin-binding protein family)LPS (Lipopolysaccharide)

Beyond the preview

Go deeper on cephalothin + tobramycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cephalothin + tobramycin.

Explore the full profile